Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH
  • Correction 27 April 2020

Breaking Eroom’s Law

  1. Michael S. Ringel

    1. Boston Consulting Group, Boston, MA 02210, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Jack W. Scannell

    1. University of Edinburgh, Edinburgh, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Mathias Baedeker

    1. Boston Consulting Group, Munich, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Ulrik Schulze

    1. Boston Consulting Group, Zürich, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Early in the last decade, researchers at Sanford Bernstein published ‘Eroom’s Law’— Moore’s Law in reverse — that the all-in cost of R&D on new drugs approved by the US FDA had risen exponentially for 60 years (Nat. Rev. Drug Discov. 11, 191–200; 2012). Among the potential contributing factors underlying the trend, the authors highlighted a progressively higher bar for improvements over existing therapies (the ‘better than the Beatles’ problem) and a progressive lowering of risk tolerance by regulatory agencies (the ‘cautious regulator’ problem). However, as the researchers posited might happen, about the same time Eroom’s Law was published, it was already being broken. Here, we analyse the changes and discuss the underlying factors. Details of the data and analysis are provided in Supplementary Box 1.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 833-834 (2020)

doi: https://doi.org/10.1038/d41573-020-00059-3

Acknowledgements

The authors thank Q. N. Vuong for analytical support and P. Kirkpatrick for valuable commentary on an earlier draft.

Updates & Corrections

  • Correction 27 April 2020: The date range on the x axis of Figure 1b erroneously began in 1940 rather than 1990 and has been corrected.

Supplementary Information

  1. Supplementary Box 1

Competing Interests

M.S.R, M.B and U.S. are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's Health Care practice.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links